LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies the effects of erismodegib (LDE225) on disseminated
tumor cells (DTCs) in patients with stage III-III estrogen receptor (ER)-negative and human
epidermal growth factor receptor 2 (HER2)-negative breast cancer. The presence of DTCs after
completing treatment for breast cancer may be linked to recurrence of the disease. LDE225 may
eliminate DTCs in bone marrow and reduce the risk of recurrence.